88 results
Keyword Imfinzi Remove keyword
-
List item
Committee for Medicinal Products for Human Use (CHMP): 19-22 April 2022
European Medicines Agency, Amsterdam, the Netherlands, from 19/04/2022 to 22/04/2022, Last updated: 12/08/2022 -
List item
Pharmacovigilance Risk Assessment Committee (PRAC): 26-29 September 2022
European Medicines Agency, Amsterdam, the Netherlands, from 26/09/2022 to 29/09/2022, Last updated: 04/07/2022 -
List item
Pharmacovigilance Risk Assessment Committee (PRAC): 29 November-2 December 2021
European Medicines Agency, Amsterdam, the Netherlands, from 29/11/2021 to 02/12/2021, Last updated: 04/10/2022 -
List item
Pharmacovigilance Risk Assessment Committee (PRAC): 10-13 January 2022
European Medicines Agency, Amsterdam, the Netherlands, from 10/01/2022 to 13/01/2022, Last updated: 07/10/202215 4.3.1. Durvalumab – IMFINZI (CAP) - EMEA/H/C/004771/SDA/009 … -
List item
Committee for Medicinal Products for Human Use (CHMP): 16-19 May 2022
European Medicines Agency, Amsterdam, the Netherlands, from 16/05/2022 to 19/05/2022, Last updated: 12/08/2022 -
List item
Committee for Medicinal Products for Human Use (CHMP): 20-23 June 2022
European Medicines Agency, Amsterdam, the Netherlands, from 20/06/2022 to 23/06/2022, Last updated: 18/08/2022 -
List item
Pharmacovigilance Risk Assessment Committee (PRAC): 7-10 June 2022
European Medicines Agency, Amsterdam, the Netherlands, from 07/06/2022 to 10/06/2022, Last updated: 31/03/2022 -
List item
Newsletters
Last updated: 05/07/2023 -
List item
Committee for Medicinal Products for Human Use (CHMP): 20-23 February 2023
European Medicines Agency, Amsterdam, the Netherlands, from 20/02/2023 to 23/02/2023, Last updated: 24/04/2023 -
List item
Pharmacovigilance Risk Assessment Committee (PRAC): 5-8 July 2021
European Medicines Agency, Amsterdam, the Netherlands, from 05/07/2021 to 08/07/2021, Last updated: 10/05/2022 -
List item
Committee for Medicinal Products for Human Use (CHMP): 24-27 January 2022
European Medicines Agency, Amsterdam, the Netherlands, from 24/01/2022 to 27/01/2022, Last updated: 16/03/2022 -
List item
Pharmacovigilance Risk Assessment Committee (PRAC): 26-29 October 2020
Virtual meeting, from 26/10/2020 to 29/10/2020, Last updated: 08/01/2021LIBTAYO (CAP); durvalumab – IMFINZI (CAP); ipilimumab – YERVOY … -
List item
Committee for Medicinal Products for Human Use (CHMP): 16-19 August 2022
Written procedure, from 16/08/2022 to 19/08/2022, Last updated: 04/10/2022 -
List item
Committee for Medicinal Products for Human Use (CHMP): 17-20 May 2021
European Medicines Agency, Amsterdam, the Netherlands, from 17/05/2021 to 20/05/2021, Last updated: 07/12/2021 -
List item
Pharmacovigilance Risk Assessment Committee (PRAC): 3-6 May 2021
European Medicines Agency, Amsterdam, the Netherlands, from 03/05/2021 to 06/05/2021, Last updated: 27/02/2018 -
List item
Pharmacovigilance Risk Assessment Committee (PRAC): 7-10 June 2021
European Medicines Agency, Amsterdam, the Netherlands, from 07/06/2021 to 10/06/2021, Last updated: 07/06/2021 -
List item
News: Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 30 August – 2 September 2021
PRAC, Last updated: 17/09/202116 4.1.3. Durvalumab – IMFINZI (CAP … -
List item
Committee for Medicinal Products for Human Use (CHMP): 12-15 December 2022
European Medicines Agency, Amsterdam, the Netherlands, from 12/12/2022 to 15/12/2022, Last updated: 06/04/2021 -
List item
News: Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 4-7 July 2022
PRAC, Last updated: 08/07/2022 -
List item
News: Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 26-29 September 2022
PRAC, Last updated: 30/09/2022 -
List item
News: Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 28 November - 1 December 2022
PRAC, Last updated: 02/12/2022 -
List item
Committee for Medicinal Products for Human Use (CHMP): 18-21 July 2022
European Medicines Agency, Amsterdam, the Netherlands, from 18/07/2022 to 21/07/2022, Last updated: 06/04/2021 -
List item
Pharmacovigilance Risk Assessment Committee (PRAC): 23-26 November 2020
Virtual meeting, from 23/11/2020 to 26/11/2020, Last updated: 27/11/2020 -
List item
News: Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 24 - 27 October 2022
PRAC, Last updated: 28/10/2022 -
List item
Pharmacovigilance Risk Assessment Committee (PRAC): 28 September-1 October 2020
Virtual meeting, from 28/09/2020 to 01/10/2020, Last updated: 29/09/2020